Results 1 to 10 of about 31,435 (210)

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up [PDF]

Breast Cancer Research and Treatment, 2019
PurposeIn the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor ...
Bartlett, C Huang, Castrellon, A, Diéras, V, Ettl, J, Finn, RS, Gauthier, ER, Gelmon, KA, Harbeck, N, Iyer, S, Joy, AA, Lipatov, O, Lu, DR, Mori, A, Rugo, HS, Slamon, DJ   +14 more
exaly   +2 more sources

A randomized controlled trial comparing combination of letrozole and clomiphene citrate or letrozole alone for ovarian stimulation in infertile women [PDF]

Journal of Family Medicine and Primary Care
Introduction: Infertility is defined by failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse. Unexplained infertility was often treated with superovulation by using clomiphene, letrozole, or gonadotropins in a ...
Anamika Kumari, Mona Asnani, Anjoo Agarwal, Renu Singh, Smriti Agrawal   +4 more
doaj   +2 more sources

Randomized interventional clinical trial to estimate the efficacy of clomiphene citrate versus letrozole in induction of ovulation in infertility [PDF]

New Indian Journal of OBGYN, 2022
Background and objectives: Anovulation accounts for 30-40% of female infertility. The treatment of choice is by ovulation induction. This study is to estimate effectiveness of clomiphene citrate versus letrozole in ovulation induction.
Yogindra Kumar Manohar Kabadi, Pavitra S Madinoor   +1 more
doaj   +1 more source

Maternal aromatase inhibition via letrozole altered RFamide-related peptide-3 and gonadotropin-releasing hormone expression in pubertal female rats [PDF]

Iranian Journal of Basic Medical Sciences, 2022
Objective(s): Despite prevalence of polycystic ovary syndrome (PCOS) among childbearing women and development of many animal models for this syndrome, information on its etiology is still scarce.
Zahra Shaaban, Amin Tamadon, Mohammad Reza Jafarzadeh Shirazi, Mohammad Javad Zamiri, Amin Derakhshanfar   +4 more
doaj   +1 more source

Poloxamer188 composite electrospun poly L-lactic acid fibrous nonwoven: Sustained and release letrozole as a subcutaneous implant

Journal of Industrial Textiles, 2022
Poloxamer188 composite poly L-lactic acid (PLLA) electrospun fibrous nonwovens (EFNW) were prepared by simple letrozole-poloxamer188-PLLA co-solution electrospinning and used as subcutaneous implants to sustained release letrozole.
Hao Wang, Jiana Huang, Yang Liu, Xin Dong, Meng Wen, Jianhua Huang   +5 more
doaj   +1 more source

The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome. [PDF]

, 2016
Women with polycystic ovary syndrome (PCOS) have reproductive and metabolic abnormalities that result in an increased risk of infertility, diabetes and cardiovascular disease.
Kelley, Scott T, Rivera, Alissa J, Skarra, Danalea V, Thackray, Varykina G   +3 more
core   +12 more sources

Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis

Frontiers in Oncology, 2022
BackgroundCyclin-dependent kinase 4/6 inhibitors are a standard treatment for patients with hormone receptor−positive (HR+)/human epidermal growth factor receptor 2−negative (HER2−) metastatic breast cancer (MBC).
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Rachel M. Layman   +4 more
doaj   +1 more source

Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model

Health Economics Review, 2023
Background Palbociclib and Ribociclib are cyclin-dependent kinase 4/6 oral molecular inhibitors that have the potential to improve overall survival (OS), progression-free survival (PFS), and quality of life in patients with metastatic breast cancer (MBC).
Ali Darvishi, Rajabali Daroudi, Ali Akbar Fazaeli   +2 more
doaj   +1 more source

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer

Breast, 2023
Background: Palbociclib, the first available cyclin-dependent kinase 4/6 inhibitor, plus endocrine therapy is approved for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (MBC).
Hope S. Rugo, Xianchen Liu, Benjamin Li, Lynn McRoy, Rachel M. Layman, Adam Brufsky   +5 more
doaj   +1 more source

Effects of letrozole co-treatment on the cumulative live-birth rate among normal responders in gonadotropin-releasing hormone antagonist cycles

Frontiers in Medicine, 2022
Studies have shown that letrozole cotreatment can improve clinical outcomes in high and poor responders in GnRH-antagonist protocol. However, whether letrozole is also beneficial to normal responders is not known.
Shuyi Zhang, Fumei Gao, Min Fu, Huan Shen, Yanbin Wang, Hongjing Han   +5 more
doaj   +1 more source